artículo
Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
Fecha
2023Registro en:
10.3390/vaccines11071193
0899-4056
Autor
Mondaca Contreras, Sebastián Patricio
Walbaum, Benjamín
Corre, Nicole Le
Ferrés Garrido, Marcela Viviana
Valdés, Alejandro
Martínez-Valdebenito, Constanza
Ruiz-Tagle, Cinthya
Macanas Pirard, Patricia
Ross, Patricio
Cisternas, Betzabé
Pérez, Patricia
Cabrera, Olivia
Cerda, Valentina
Ormazábal, Ivana
Barrera Vásquez, Aldo Vincen
Prado, María E.
Venegas, María I.
Palma, Silvia
Broekhuizen, Richard
Kalergis, Alexis
Bueno, Susan M.
Espinoza, Manuel A.
Balcells Marty, María Elvira
Nervi Nattero, Bruno
Institución
Resumen
Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8–12 weeks post-booster. The secondary end points included IgG antibody (TAb) seropositivity and specific T-cell responses. A total of 109 patients were included. Eighty-four (77%) had heterologous vaccine schedules (two doses of CoronaVac followed by the BNT162b2 booster) and twenty-five had (23%) homologous vaccine schedules (three doses of BNT162b2). IgG antibody positivity for the homologous and heterologous regimen were 100% and 96% (p = 0.338), whereas NAb positivity reached 100% and 92% (p = 0.13), respectively. Absolute NAb positivity and Tab levels were associated with the homologous schedule (with a beta coefficient of 0.26 with p = 0.027 and a geometric mean ratio 1.41 with p = 0.044, respectively). Both the homologous and heterologous vaccine regimens elicited a strong humoral and cellular response after the BNT162b2 booster. The homologous regimen was associated with higher NAb positivity and Tab levels after adjusting for relevant covariates.